PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24644001-0	2014	Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.	Metformin	0-9	epidermal growth factor receptor	Homo sapiens	21-25	
24644001-4	2014	This study aims to investigate the effect of metformin on sensitizing EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.	Metformin	45-54	epidermal growth factor receptor	Homo sapiens	70-74	
24644001-10	2014	CONCLUSION: Metformin, generally considered nontoxic and remarkably inexpensive, might be used in combination with TKIs in patients with non-small cell lung cancer, harboring EGFR mutations to overcome TKI resistance and prolong survival.	Metformin	12-21	epidermal growth factor receptor	Homo sapiens	175-179